Your browser doesn't support javascript.
loading
Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis.
Ohri, Nitin; Halmos, Balazs; Bodner, William R; Cheng, Haiying; Garg, Madhur K; Gucalp, Rasim; Guha, Chandan.
Affiliation
  • Ohri N; Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York. Electronic address: nitin.ohri@einsteinmed.org.
  • Halmos B; Department of Hematology/Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York.
  • Bodner WR; Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York.
  • Cheng H; Department of Hematology/Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York.
  • Garg MK; Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York.
  • Gucalp R; Department of Hematology/Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York.
  • Guha C; Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York.
Pract Radiat Oncol ; 11(2): e172-e179, 2021.
Article in En | MEDLINE | ID: mdl-33127337
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pract Radiat Oncol Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pract Radiat Oncol Year: 2021 Document type: Article